Wegovy 0.5mg weight loss results: what does this dose actually do?

Is 0.5mg actually supposed to produce weight loss, or is it just a stepping stone?

Honest answer: mostly the latter. The 0.5mg weekly dose is the second rung of Wegovy's titration schedule, typically reached after a month at 0.25mg, and if you are curious about what that first month tends to deliver, you can find a detailed breakdown on our page covering Wegovy 0.25 mg weight loss results. The purpose of these early weeks is to let your body acclimatise to semaglutide, to reduce the likelihood of nausea and other gastrointestinal effects that tend to be sharpest when the dose rises quickly. You can read more about how the full schedule unfolds on the Wegovy doses guide.

That said, some people do notice appetite changes and a little weight movement at 0.5mg. Semaglutide acts on GLP-1 receptors involved in appetite signalling and gastric emptying, so even a low dose begins to shift how hungry you feel between meals. For some, that alone produces a few kilograms of early loss. For others, the scale barely moves until the dose climbs higher. Both experiences are normal and neither tells you much about how you will respond at 2.4mg.

The STEP 1 trial, published in the New England Journal of Medicine, enrolled adults without diabetes and reported around 15% average weight reduction over 68 weeks at the 2.4mg maintenance dose. The 0.5mg phase was a passage to get there, not a destination in itself. Keeping that in mind makes the early weeks less frustrating.

What do most people experience during the 0.5mg month?

The most common report is a noticeable, if not dramatic, reduction in appetite, particularly for larger portions and high-fat foods. Cravings can quieten down before the scales shift, and for many people that is actually the more useful early signal: the medicine is doing something, even if it is not yet visible as lost weight.

Side effects are real at this stage. Nausea is the most frequently reported, along with loose stools, indigestion, and occasional burping or reflux. These tend to peak in the first few days after each injection and then ease over the week. They are generally milder at 0.5mg than they will be after the next increase, but they are also more noticeable than most people experienced at 0.25mg. Staying well hydrated and eating smaller, lower-fat meals makes a practical difference.

Injection-site reactions (mild redness or a little discomfort at the abdomen, thigh or upper arm) are also possible. Rotating sites weekly helps. The pen itself is straightforward to use; the Wegovy overview covers storage and handling in more detail. For anything beyond mild symptoms, or for anything that feels urgent, your prescriber and the Patient Information Leaflet are the right first ports of call, not a web search.

The NHS medicines page for semaglutide has a thorough list of side effects and what to do about them, and is worth bookmarking for reference during your early weeks on treatment.

When should I expect to see more meaningful results, and how does 0.5mg compare to later doses?

For most people, the more significant weight-loss results come once the maintenance dose of 2.4mg is reached and sustained. The titration period, including the 0.5mg month, is preparation. It typically takes four to five months of gradual dose increases before reaching 2.4mg, and the full effect at that dose builds over many more months beyond that.

If you want a sense of what the later stages tend to look like, the results at 1mg and at 2.4mg are covered in dedicated pages. The pattern is consistent: weight loss tends to accelerate as the dose increases, with the steepest reduction coming in the first six to nine months at the maintenance dose before plateauing.

One thing worth knowing: Wegovy is now also licensed in the UK at a higher maintenance dose of 7.2mg, approved by the MHRA in January 2026, for adults with a BMI of 30 or above. Early trial data at that dose showed average weight loss approaching 20–21% over 72 weeks, narrowing the gap with tirzepatide. Whether that option is clinically appropriate is a prescriber's assessment. For context on how results compare across the two main licensed injectable treatments, the weight loss treatment overview sets out the key differences.

Does it matter that I am not losing much at 0.5mg, should I be concerned?

Generally, no. Slow or minimal loss during titration is expected and does not predict poor response at therapeutic doses. Prescribers assess progress at the maintenance dose, not during the stepping-up phase. NICE's clinical review of semaglutide, set out in NICE guidance TA875, recommends considering whether to continue only if less than 5% weight loss has been achieved after six months on the maintenance dose, not during titration.

If you are concerned that side effects at 0.5mg are particularly severe, or that something feels wrong, contact your prescriber rather than adjusting the dose yourself. Titration timing, pausing at a dose for longer, and decisions about when to increase are clinical calls. If you are considering starting Wegovy through a regulated private service, this page on getting Wegovy online explains what the process looks like and what makes a pharmacy legitimate to use. At nume, a real prescriber (not an algorithm) reviews every consultation the same day it is submitted, and your first order arrives via tracked DPD delivery in plain, unbranded packaging. If you would like to explore whether Wegovy is clinically suitable for you, start your free consultation with our prescribing team.